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Abstract A combination of genetic variations, epimuta-
tions and environmental factors may be involved in the
etiology of complex neurodevelopmental disorders like
schizophrenia. To study such disorders, we use apomor-
phine-unsusceptible (APO-UNSUS) Wistar rats and their
phenotypic counterpart apomorphine-susceptible (APO-
SUS) rats that display a complex phenotype remarkably
similar to that of schizophrenic patients. As the molecular
basis of the APO-SUS/UNSUS rat model, we recently
identiﬁed a genomic rearrangement of the Aph-1b gene.
Here, we discovered between the two rat lines differences
other than the Aph-1b gene defect, including a remarkable
cluster of genetic variations, two variants corresponding to
topoisomerase II-based recombination hot spots and an
epigenetic (DNA methylation) difference in cerebellum
and (hypo)thalamic but not hippocampal genomic DNA.
Furthermore, genetic variations were found to correlate
with the degree of apomorphine susceptibility in unselected
Wistar rats. Together, the results show that a number of
genetic and epigenetic differences exist between the APO-
SUS and -UNSUS rat genomes, raising the possibility that
in addition to the Aph-1b gene defect the newly identiﬁed
variations may also contribute to the complex APO-SUS
phenotype.
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Introduction
Schizophrenia is a neurodevelopmental disorder affecting
nearly 1% of the world’s population (Jablensky et al.
1987), and is characterized by positive and negative
symptoms (Kay and Opler 1987). The aetiology of
schizophrenia and other related disorders, such as schizo-
affective and bipolar disorder, is still unclear. Twin, family
and adoption studies have suggested that complex inter-
actions at the genetic and environmental level underlie the
aetiology of schizophrenia (Gottesman 1991). It is thought
that gene variations by themselves do not result in
schizophrenia, but they can establish a predisposition status
that, when combined with environmental stressors, may
lead to schizophrenia pathogenesis. Numerous environ-
mental factors, such as viral infections (Mednick et al.
1988), insufﬁcient folate and methionine levels (Regland
2005), or repeated psychological stress (Goldstein 1987),
can inﬂuence brain development of prenatal or early
postnatal individuals with a genetic predisposition for
neuropsychiatric disorders. Due to the heterogeneity in
genetic and environmental interactions, most of the genes
and pathways for schizophrenia and for other complex
disorders are still unknown.
To get insight into the gene (or genes) that may be
involved in schizophrenia pathogenesis, a rat model was
developed with schizophrenia-like features. This model
was based on the behavioural response of Wistar rats to the
dopamine agonist apomorphine (Cools et al. 1990). The
apomorphine-susceptible (APO-SUS) rat line displayed
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bances at the behavioural, physiological, endocrinological
and pharmacological level as seen in schizophrenics (El-
lenbroek and Cools 2002). For example, APO-SUS rats
have a reduced prepulse inhibition and latent inhibition
(Ellenbroek et al. 1995), display a higher plasma release of
adrenocorticotropin (ACTH) and corticosteroids in
response to novelty (Rots et al. 1995), are more sensitive to
dopamimetic drugs (Ellenbroek et al. 2000), and have a
higher susceptibility to inﬂammatory and infectious dis-
eases when compared to apomorphine-unsusceptible
(APO-UNSUS) rats (Kavelaars et al. 1997). We therefore
wondered about the molecular-genetic basis underlying the
APO-SUS/-UNSUS rat model and recently identiﬁed a
genetic difference between the two rat lines (Coolen et al.
2005). Whereas APO-UNSUS rats harbour three gene
copies of the c-secretase component Aph-1b, APO-SUS
rats have only one or two copies. This gene-dosage
imbalance was due to an unequal crossing over event
(nonallelic homologous recombination) between two direct
repeats (a segmental duplication) within the Aph-1b locus.
In addition, we observed a direct link between the Aph-1b
genotypes and a number of phenotypic APO-SUS and
-UNSUS characteristics (Coolen et al. 2005). Approxi-
mately 10 years after developing the APO-SUS and
-UNSUS lines a second, independent breeding procedure
was started that resulted in rats with features similar to
those displayed by the original APO-SUS and -UNSUS rat
lines (Ellenbroek and Cools 2002). Interestingly, the rep-
licated rat lines also resulted in APO-UNSUS rats with
three Aph-1b gene copy numbers and APO-SUS rats with
only one or two gene copies (Coolen et al. 2005).
In the present study, we wondered whether genetic
variations other than the Aph-1b gene-dosage imbalance
may be present between the APO-SUS and -UNSUS rats,
and whether epigenetic factors may be involved as well.
Epigenetics has been deﬁned as heritable changes in gene
expression that do not occur by changes in the DNA
sequence, but by modiﬁcations in DNA methylation and
chromatin remodeling (Wolffe and Matzke 1999), or, in its
widest sense, as any change in an organism that is not due
to genetic factors (Van de Vijver et al. 2002). Increasing
evidence suggests that epigenetic modiﬁcations play a role
in disease susceptibility (reviewed by Jirtle and Skinner
2007). We used the arbitrarily primed-polymerase chain
reaction (AP-PCR) ﬁngerprinting technique (Welsh and
McClelland 1990) to analyse the genomes and epigenomes
(DNA methylation) of the APO-SUS and -UNSUS rats.
Comparison of the AP-PCR ﬁngerprints generated from the
genomic DNAs of the two rat lines revealed genetic as well
as epigenetic alterations and we conclude that, besides in
the Aph-1b locus, a number of other variations are present
in the APO-SUS and -UNSUS genomes and epigenomes.
Materials and methods
Experimental animals
The generation of the APO-SUS and -UNSUS rat lines
with a high or low susceptibility for apomorphine,
respectively, has been described previously (Cools et al.
1990). The present experiments were performed with male
APO-SUS and -UNSUS rats belonging to the 32nd
(original lines) and 18th (replicate lines) generation. At
post-natal day 60 (PND60), APO-SUS and -UNSUS rats
were sacriﬁced and the hippocampus, cerebellum and the
combined thalamus/hypothalamus (further denoted as
(hypo)thalamus) were isolated. To establish their apomor-
phine susceptibility, unselected male Wistar rats of the
Nijmegen outbred population (PND60) were injected with
apomorphine (1.5 mg/kg s.c.) and gnawing scores were
measured in a gnawing box for 45 min, as described pre-
viously (Cools et al. 1990). Immediately following the
measurements, the rats were sacriﬁced and the same tissues
(hippocampus, cerebellum and (hypo)thalamus) were
removed. All rats were bred and reared in the Central
Animal Facility of the Radboud University Nijmegen
under approved animal protocols and in accordance with
institutional guidelines.
Arbitrarily primed-PCR
Genomic DNAs were isolated from hippocampus, cere-
bellum and (hypo)thalamus using standard procedures
involving the use of proteinase K and phenol extraction.
Two micrograms of genomic DNA were digested with
20 units of RsaI, 20 units RsaI in combination with the
methylation-sensitive enzyme HpaII, or 20 units RsaI and
MspI (MBI Fermentas) in a total volume of 40 lla t3 7 C
for 16 h. HpaII does not cut DNA if the internal cytosine
(CCGG) is methylated, whereas MspI is insensitive to
DNA methylation. Using such combinations of
methylation-sensitive and -insensitive enzymes allows
genome-wide screening for differences at the genetic level
(single-nucleotide polymorphisms––SNPs, duplications,
insertions, deletions and recombinations) as well as the
epigenetic (DNA methylation) level. Restriction enzymes
were heat inactivated by incubating the reactions at 65C
for 20 min. Digested DNA (100 ng) was ampliﬁed using
AP-PCR (Welsh and McClelland 1990) with a single pri-
mer. PCRs were performed in a total volume of 25 ll
containing 10 mM Tris-HCl (pH 8.3), 2.5 mM MgCl2,
50 mM KCl, 0.001% gelatin, 0.25% Nonidet P-40, 0.25%
Tween-20, 200 lM each of the four deoxynucleotide tri-
phosphates, *1 lCi of [a-
32P]dCTP (3000 Ci/mmol,
Amersham Corp.), 25 pmol of primer (AP-1: 50-AAC
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CTAAGGCGCG-30, AP-777: 50-CACTCCTCTACAAGG
TGCCG-30 or Topo: 50-GCCTCCTTGCAGGTCTTT-30),
and 0.8 units of Taq polymerase (MBI Fermentas). Reac-
tions were carried out in a thermal cycler (Perkin-Elmer)
with ﬁve cycles of low stringency (94C for 30 s, 40C for
60 s, 72C for 1.5 min), followed by 30 cycles of high
stringency (94C for 15 s, 55C for 15 s, 72C for 1 min).
Two microliters of the PCR products were analysed on
high-resolution 5% polyacrylamide gels under denaturing
conditions (7 M urea) for 4–4.5 h at 70 W. Gels were dried
and radiolabelled DNA was visualized by autoradiography
at –70C (CEA AB, Sweden).
Cloning and sequencing of AP-PCR fragments
AP-PCR fragments generated from APO-SUS and -
UNSUS rat genomic DNAs were excised from the dried
gels and incubated in 50 ll MilliQ at 80C for 10 min. The
eluted DNA (two microliters) was reampliﬁed with the
same primer as used for the AP-PCR to generate sufﬁcient
amounts of template for subsequent cloning. The reactions
were carried out for 40 cycles of 94C for 1 min, 55C for
30 s, 72C for 1 min, under the same conditions as
described in the AP-PCR protocol (except that
[a-
32P]dCTP was not included). The PCR products were
puriﬁed, cloned into the pGEM-T easy vector (Promega)
and sequenced with a T7 or Sp6 primer according to the
manufacturer’s instructions using the ABI310 machine
(Applied Biosystems).
Sequencing and genotyping of chromosomal region
9q22
A 1948-bp fragment that harbours the nucleotide sequence
corresponding to product 3 was obtained by PCR on
genomic DNA derived from (hypo)thalamic tissue of an
APO-UNSUS rat using forward primer 50-GGGAAGCA
ACGCATCCTG-30 and reverse primer 50-CATATCAAAG
CACCAAGTCCACAG-30. The DNA was subsequently
puriﬁed and directly sequenced using the ABI310 machine
(Applied Biosystems). Genotyping of chromosomal region
9q22 was performed with PCR using primers speciﬁc for
either the APO-SUS or APO-UNSUS genomic sequence.
Brieﬂy, PCRs were performed in a total volume of 20 ll
containing 50 ng genomic DNA, 10 mM Tris-HCl (pH
8.3), 2.5 mM MgCl2, 50 mM KCl, 0.001% gelatin, 0.25%
Nonidet P-40, 0.25% Tween-20, 200 lM each of the four
deoxynucleotide triphosphates, 0.6 lM of each primer
(FW: 50-AACACTTGGACTCATTCTCACTGG-[G (SUS)
or T (UNSUS)]-30 and RV: 50-CCTGGATGGAATGTTG
ACAC-[C (SUS) or T (UNSUS)]-30), and 0.8 units of Taq
polymerase (MBI Fermentas). Reactions were carried out
at 94C for 60 s, 58C for 60 s and 72C for 60 s for 35
cycles. Products were analysed on a 1% agarose gel.
Quantiﬁcation and statistics
Quantiﬁcation of AP-PCR products was performed using
the Labworks 4.0 program (UVP BioImaging Systems,
Cambridge, UK) and statistical evaluation was performed
by means of an unpaired Student’s t-test.
Results
AP-PCR DNA ﬁngerprint patterns of the APO-SUS and
APO-UNSUS rat genomes and epigenomes
In order to identify differences between the genomes and
epigenomes of APO-SUS and -UNSUS rats, we performed
a comparative analysis of ﬁngerprints of AP-PCR products
generated from genomic DNAs of the two rat lines.
Initially, genomic DNAs isolated from APO-SUS and
-UNSUS (hypo)thalamic tissue and digested with RsaIi n
combination with the methylation-sensitive restriction
enzyme HpaII (CCGG) was analysed using arbitrary
primers AP-1, AP-7 or AP-777. These primers were
selected from a total set of ten primers because they gave
ﬁngerprints with reproducible and discrete products (data
not shown). Typical AP-PCR ﬁngerprints obtained with the
three selected arbitrary primers are shown in Fig. 1. With
each arbitrary primer *30 chromosomal fragments were
reproducibly ampliﬁed. DNAs digested with RsaI and the
methylation-insensitive enzyme MspI served as controls to
determine whether the observed differences were due to a
differential methylation of the CCGG sequence or a genetic
polymorphism in this sequence. AP-PCR analysis with
primer AP-1 revealed 16 products corresponding to frag-
ments without an HpaII site (‘‘genetic fragments’’) and 23
products corresponding to fragments containing an HpaII
site (‘‘epigenetic fragments’’). Analysis with AP-PCR pri-
mer AP-7 showed 17 genetic and 11 epigenetic fragments,
and with AP-777 primer 22 genetic and 6 epigenetic
fragments.
Genetic variations between the APO-SUS and APO-
UNSUS rat genomes
Comparison of the genetic ﬁngerprints generated with
primers AP-1, -7 and -777 revealed three reproducible
variations between the genomic DNAs from the original
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123(F32) APO-SUS and -UNSUS rats, designated products 1,
2 and 3 (Fig. 2a). Product 1 was less prominent in the
APO-SUS than in the APO-UNSUS rats, product 2 was
found only in APO-SUS, while the level of product 3 was
higher in the APO-SUS than -UNSUS rats. Interestingly,
the three products were also present in the replicate (F18)
lines and at the same levels, indicating that the replication
of the APO-SUS and -UNSUS lines had resulted in a
similar genotypic distribution. Next, digestions using RsaI
in combination with MspI were used to examine whether
the observed differences were due to a genetic or an epi-
genetic alteration. Following digestion with RsaI and MspI,
products 1, 2 and 3 were still found, indicating that the
presence of the three AP-PCR products was due to genetic
differences (Fig. 2b).
We previously discovered that the Aph-1b gene-dosage
imbalance between the APO-SUS and -UNSUS rats is the
result of a DNA recombination event between the two Aph-
1b genes. Furthermore, we identiﬁed the region in which
the recombination occurred, namely in a region of 1106
nucleotides that is identical between the two genes and
encompasses exon 5 (Coolen et al. 2005). In the present
study, we decided to examine in detail the site of recom-
bination and found a topoisomerase II binding site (50-AC
CCACCTGCTGGTGTCC-30) in the DNA region
harbouring the recombination site. Topoisomerase II
binding sites (with the vertebrate consensus sequence 50-R
NYNNCNNGYNGKTNYNY-30) (Spitzner and Muller
1988) are known to be hotspots where DNA recombination
events occur easily (Craig and Nash 1983). We therefore
wondered whether other topoisomerase II binding sites
could have led to additional differences between the APO-
SUS and -UNSUS rat genomes. Interestingly, using a pri-
mer based on the topoisomerase II binding site consensus
for PCR analysis of genomic DNAs digested with EcoRIo r
MboI revealed two differences between the APO-SUS
(n = 3) and -UNSUS (n = 2) rat genomes of the original
(F32) lines, designated products 4 and 5 (Fig. 2c). Product
4 was present in APO-SUS but not in APO-UNSUS rat
genomic DNA. In the replicate APO-SUS and -UNSUS
Fig. 1 AP-PCR analysis of genomic DNAs from APO-UNSUS (U)
and APO-SUS (S) (hypo)thalamus. AP-PCR was performed with
primers AP-1, AP-7 and AP-777 using genomic DNAs digested with
RsaI and HpaII (H) or RsaI and MspI (M) as templates. Epigenetic
products (methylation-sensitive and thus absent in the MspI lanes) are
indicated by closed arrows and genetic products (methylation-
insensitive and thus present in the MspI lanes) by open arrows
Fig. 2 Genetic variations in genomic DNAs from APO-SUS (S) and
APO-UNSUS (U) (hypo)thalamus. Rats were from the original (F32)
or the replicate (F18) rat lines. (A) Products generated by AP-PCR
using primers AP-1 (product 1), AP-7 (product 2) or AP-777 (product
3) on genomic DNAs digested with the methylation-insensitive
enzyme RsaI and the methylation-sensitive enzyme HpaII. ND = not
determined. (B) Products 1, 2 and 3 generated by AP-PCR on
genomic DNAs digested with RsaI and HpaII (H) or with the two
methylation-insensitive enzymes RsaI and MspI (M). MspI products
served as controls to determine whether products 1, 2 and 3 were due
to differential methylation or to a genetic polymorphism. The fact that
products 1, 2 and 3 were still present following MspI digestion
indicates that they represent products without an HpaII site (‘‘genetic
fragments’’). (C) Products generated by AP-PCR using a topoiso-
merase II binding site consensus sequence (50-GCCTCC
TTGCAGGTCTTT-30) on genomic DNAs digested with the methyl-
ation-insensitive enzymes EcoRI (product 4) or MboI (product 5).
Arrows indicate increased amounts of the AP-PCR products
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123lines (F18), the genomes of two APO-UNSUS rats did also
not contain product 4, whereas it was present in two of the
four APO-SUS rats tested. Product 5 was present in three
of the four APO-UNSUS rats examined (in both the ori-
ginal and the replicate lines), whereas it was not observed
in the seven APO-SUS rats tested (Fig. 2c).
Epigenetic variations between the APO-SUS and APO-
UNSUS rat genomes
We then wondered whether, besides the ﬁve genetic vari-
ations, also epigenetic variations would be present between
the APO-SUS and -UNSUS rat lines. AP-PCR analysis
using primer AP-1 on RsaI- and HpaII-digested genomic
DNAs from APO-SUS and -UNSUS (hypo)thalamus
revealed one epigenetic variation, designated the
E1-product (Fig. 3a). The difference was observed in both
the original APO-SUS and -UNSUS rats as well as the
replicated lines. An *1.4-fold reduced amount of the
E1-product was observed in APO-SUS when compared
with APO-UNSUS genomic DNAs (n = 12, P\0.05).
Since DNA methylation may be tissue speciﬁc, we decided
to examine the E1-product in two other brain tissues. The
level of the E1-product was *2-fold reduced in genomic
DNAs from the cerebellum of APO-SUS compared to
APO-UNSUS rats (n =4 ,P\0.01), while no difference in
the E1-levels was found in the hippocampus of the
APO-SUS and -UNSUS rats (n = 4).
Chromosomal localizations of the genetic
and epigenetic variations between the APO-SUS
and -UNSUS rat genomes
To identify the locations of the genetic and epigenetic
variations within the APO-SUS and -UNSUS rat genomes,
AP-PCR fragments 1, 2, 3 and E1 were excised from the
gel and each fragment was reampliﬁed with the primer
used for the original AP-PCR reaction. DNA sequence
analysis of the ampliﬁed PCR fragments and database
searches with the obtained nucleotide sequences revealed
the chromosomal localisations of the four fragments;
product 1 was located on chromosome 19q11, *3.3 kb
upstream of the ﬁrst exon of the GAIP-interacting protein,
C terminus (GIPC) gene; product 2 was part of a repeat
sequence located on chromosome 2q34; product 3 was
located in the ﬁrst intron of the myosin 1b gene on chro-
mosome 9q22; the epigenetic variation E1 was located on
chromosome 6q31, downstream of the Jun dimerization
protein 2 (NP_446346.1) and upstream of the ATF-like
basic leucine zipper transcriptional factor B-ATF (SF-HT-
activated gene 2; XP_216745.2). Since product 3 was
localized within a gene, we decided to analyse this chro-
mosomal region in more detail. Sequence analysis of the
DNA region corresponding to AP-PCR fragment 3 and its
surrounding region revealed a remarkably high number of
genetic variations: 10 of the 1948 base pairs analysed were
different between the APO-SUS and -UNSUS genomes
(Fig. 4). Comparison of the nucleotide sequences of the
APO-SUS and -UNSUS DNA regions with the corre-
sponding database sequence (geneID: 117057) revealed a
100% identity between the database and the APO-UNSUS
sequences, indicating that the APO-SUS genome has
diverged from the database sequence. Next, more APO-
SUS and -UNSUS rats were genotyped for this region. All
APO-UNSUS rats tested (n = 5) indeed showed the data-
base sequence, whereas the APO-SUS rats tested (n =5 )
all contained the relatively high number of variations in
this chromosomal region.
The newly identiﬁed genetic and epigenetic variations,
and apomorphine susceptibility in Wistar rats
We wondered whether the molecular-genetic difference
between the APO-SUS and -UNSUS rats (the Aph-1b gene-
Fig. 3 Epigenetic variation in genomic DNAs from APO-SUS (S)
and APO-UNSUS (U) (hypo)thalamus. Rats were from the original
(F32) or the replicate (F18) rat lines. (A) Product E1 generated by AP-
PCR using primer AP-1 on genomic DNAs digested with RsaI and
HpaII. Arrow indicates a representative example of an AP-PCR
product that did not show variable amounts using primer AP-1
(randomly chosen out of 38 products) and was used for normalization.
(B) The AP-PCR E1-product generated from genomic DNAs from
cerebellum, hippocampus and (hypo)thalamus. All rats were from
different nests. The products indicated by the arrow were used for
normalisation. Amounts for the epigenetic E1-product were signiﬁ-
cantly different between the APO-SUS and APO-UNSUS rats in the
cerebellum (**P\0.01; n = 4, plus s.e.m.) and (hypo)thalamus
(*P\0.05; n = 12, plus s.e.m.), but not in the hippocampus (n =4 ,
plus s.e.m.)
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123dosage imbalance) would also be present in the Nijmegen
outbred population of Wistar rats, or if the imbalance was
generated during the breeding of the rat lines. PCR analysis
of the Aph-1b locus in the 50 Wistar rats examined
revealed in all cases the presence of three copies of the
Aph-1b gene, suggesting that the reduction of Aph-1b
copies in the APO-SUS rats had been induced during the
breeding of the rats.
We next wondered whether the newly identiﬁed genetic
and epigenetic variations in the APO-SUS and -UNSUS
genomes were also induced during the breeding of the two
rat lines, or if these variants are already present in Wistar
rats. For this purpose, we performed AP-PCR analysis of
(hypo)thalamic genomic DNAs from Wistar rats using
primers AP-1, -7 and -777. The ﬁngerprints revealed the
presence of the APO-SUS as well as the -UNSUS variants
of the genetic products 1, 2 and 3 (n = 8) and the epige-
netic E1-product (n = 4) in Wistar rats (Fig. 5), indicating
that the newly identiﬁed variations were not induced during
breeding of the APO-SUS and -UNSUS lines, but were
already present in the original Wistar population.
To study whether the presence or absence of the genetic
AP-PCR products observed in the APO-SUS and -UNSUS
rats (products 1, 2 and 3) was linked to the apomorphine
susceptibility of Wistar rats, we examined a group of ﬁve
rats with low susceptibility to apomorphine (\10 gnaws
per 45 min) and a highly susceptible group of three rats
([500 gnaws per 45 min). Product 1, which was less
abundant in APO-SUS than -UNSUS rats, was not present
in the three Wistar rats with high gnawing scores, but was
also not found in two of the ﬁve Wistar rats with low
gnawing scores. Of the eight rats examined, the APO-SUS-
speciﬁc product 2 was found in two Wistar rats with a high
and only one rat with a low degree of apomorphine sus-
ceptibility. The DNA region corresponding to product 3
was found twice as the APO-UNSUS sequence in the group
consisting of the low-apomorphine-susceptible Wistar rats
and once in the group of the high-apomorphine-susceptible
rats (Fig. 5a). These results indicate that none of the three
products was directly linked to the apomorphine suscepti-
bility of the Wistar rats. However, apomorphine
susceptibility may not be the result of only a single genetic
variation, but rather of multiple genetic and epigenetic
alterations. Interestingly, 67% of the three genetic products
present in the Wistar rats with low apomorphine suscepti-
bility were also found in the APO-UNSUS genome, and
78% of the three products in Wistar rats with high apo-
morphine susceptibility were APO-SUS-speciﬁc variants
(Fig. 5a), indicating that a combination of the three genetic
products may well be linked to apomorphine susceptibility.
To study the link between the epigenetic E1-product and
apomorphine susceptibility, two Wistar rats with low
gnawing scores and two with high gnawing scores were
examined for the amount of the E1-product in the cere-
bellum. Similar amounts of the E1-product as detected in
APO-UNSUS rats were found in one Wistar rat with a low
and in one Wistar rat with a high gnawing score. The
amount of the E1-product detected in APO-SUS rats was
found in one Wistar rat with low and in one Wistar rat with
high apomorphine susceptibility, indicating that no direct
link exists between the E1-product and apomorphine sus-
ceptibility. As observed in the APO-SUS and -UNSUS rats,
no variation was detected in the level of the E1-product in
hippocampal genomic DNAs from the four Wistar rats
tested (Fig. 5b).
Discussion
In this study, we investigated the genetic and epigenetic
background of the phenotypically well-characterized APO-
SUS and -UNSUS rats. Unravelling the molecular basis of
this rat model may help in our understanding of complex
human neurodevelopmental disorders, since many of the
characteristics of the APO-SUS rat line are also observed
in schizophrenic patients (Ellenbroek and Cools 2002). We
recently identiﬁed a gene-dosage imbalance in the Aph-1b
locus of the APO-SUS and -UNSUS rats, leading to a
Fig. 4 Nucleotide sequence of
chromosomal region 9q22,
corresponding to product 3, in
APO-SUS and APO-UNSUS
rats. APO-SUS/-UNSUS
genomic variations are indicated
between brackets; the ﬁrst
nucleotide represents the APO-
UNSUS sequence, the second
nucleotide the APO-SUS
sequence. The nucleotide
sequences corresponding to the
annealing sites of arbitrary
primer AP-777 are underlined
702 Behav Genet (2007) 37:697–705
123reduced expression of the Aph-1b gene in APO-SUS rats
and a segregation with a number of behavioural parameters
(Coolen et al. 2005). Here, we used AP-PCR analysis as an
approach to explore the presence of any other alterations in
the two genomes and epigenomes. We indeed identiﬁed
additional genetic and epigenetic variations, indicating that
the Aph-1b locus might not be solely responsible for the
observed phenotypes of the two rat lines and suggesting a
multi-genetic and -epigenetic origin of the differences
observed between the APO-SUS and -UNSUS rats.
Importantly, we found similar AP-PCR patterns in both the
original and replicate APO-SUS and -UNSUS lines. It is
therefore highly unlikely that the observed variations
between the APO-SUS and -UNSUS rat genomes were
simply due to coincidence.
Detailed analysis of one of the newly identiﬁed genetic
alterations (in the DNA region corresponding to product 3)
revealed in APO-SUS rats a cluster of variations in the
myosin 1b gene. Hence, this cluster appears to be a hotspot
for genetic instability. Product 1 was located upstream of
the GIPC gene encoding a protein interacting with
membrane-associated and transmembrane proteins,
including the dopamine receptors D2 and D3 (Jeanneteau
et al. 2004). The genetic variation in this locus may
therefore contribute to the differences in apomorphine
susceptibility between the APO-SUS and -UNSUS rat
lines. We also identiﬁed genetic alterations using a primer
corresponding to a topoisomerase II binding site consensus.
The rationale for this study was based on our present
ﬁnding that a topoisomerase II binding site was located at
the recombination site in the Aph-1b locus. The two newly
identiﬁed, topoisomerase II-based genetic variations might
point to a more general role for topoisomerase II binding
sites in psychopathological mechanisms. We hypothesize
that at these sites environmental factors, such as stress
during early development, may cause an increase in the
incidence of recombination and other mutagenic events,
leading to brain dysfunction and affected behavior. Besides
the genetic differences, one tissue-speciﬁc epigenetic var-
iation was found between the APO-SUS and -UNSUS
epigenomes. At present it is not clear what, if any, func-
tional consequence should be attributed to the decrease in
Fig. 5 AP-PCR analysis (products 1, 2 and E1) and speciﬁc PCR
(product 3) analysis of genomic DNAs from Wistar rats with low or
high apomorphine susceptibility. (A) The presence or absence of
products 1, 2 and 3 (genetic differences) was analysed in genomic
DNAs from the (hypo)thalamus of Wistar rats with low (\10 gnaws
in 45 min) or high ([500 gnaws in 45 min) apomorphine suscepti-
bility. U: APO-UNSUS, S: APO-SUS. Lower panel: the amounts of
the three products present in the Wistar rats were compared with the
amounts found in the APO-SUS and -UNSUS rats. (j) the genotype
of the genetic products 1, 2 or 3 in the Wistar rats with low
apomorphine susceptibility is similar to the products 1, 2 and 3
genotype of the APO-UNSUS rats; (h) the genotype in the Wistar
rats with low apomorphine susceptibility deviates from the
APO-UNSUS genotype; ( ) the genotype in the Wistar rats with
high apomorphine susceptibility is comparable with the genotype in
the APO-SUS rat; ( ) the genotype in the Wistar rats with high
apomorphine susceptibility deviates from the genotype in the
APO-SUS rats. (B) AP-PCR analysis of the epigenetic E1-product
(E1) on genomic DNAs from cerebellum and hippocampus of four
Wistar rats. The product indicated by the arrow is an example of a
product that did not show variable amounts and was used for
normalisation of the E1-product. The amounts of the E1-products
generated from the cerebellum or hippocampus were not different
between the two Wistar rats with low gnawing scores (\10 gnaws in
45 min) and the two Wistar rats with high gnawing scores
([500 gnaws in 45 min)
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123the methylation status of this CpG in the (hypo)thalamus
and cerebellum, but not in the hippocampus, of APO-SUS
relative to APO-UNSUS rats.
Earlier microarray analysis of mRNA expression in the
hippocampus of the APO-SUS and -UNSUS rats (*7000
full-length sequences and *1000 EST clusters) revealed
that only Aph-1b was differentially expressed (Coolen et
al. 2005). The newly identiﬁed variations open the possi-
bility that for an explanation of the background of the rat
model one has to consider more genes that operate together
in a multi-genetic and -epigenetic setting with several
susceptibility loci. Thus, based on our present ﬁndings,
more than one locus may be responsible for the complex
phenotype of APO-SUS rats. Recently, it has been estab-
lished that the contribution of genetic modiﬁers is also of
importance for the outcome of a phenotype, since they can
modulate the severity of the affected phenotype and the
phenotypic characteristics without having a clear effect on
the normal situation (Nadeau 2001; Nadeau and Topol
2006). Hence, as part of the genetic and epigenetic back-
ground of the APO-SUS and -UNSUS rat lines, our newly
identiﬁed variants can be genetic and epigenetic modiﬁers
inﬂuencing the phenotypic expression of the model. Insight
into the genetic and epigenetic background may provide
diagnostic tools, and clues for mechanisms and pathways to
explain complex disorders.
Besides the multiple variations in the APO-SUS and
-UNSUS rat genomes and epigenomes, Aph-1b will pre-
sumably be a major player in the development of the
complex APO-SUS phenotype, since it has a broad cellular
effect via tissue-speciﬁc cleavage of many different sub-
strates (Coolen et al. 2006b) and is functional already
during early development (Coolen et al. 2006a). Remark-
ably, however, the number of Aph-1b gene copies was not
linked to apomorphine susceptibility in Wistar rats.
Whereas their apomorphine susceptibility varied, all
unselected Wistar rats tested harboured three copies of the
Aph-1b gene. Therefore, genetic and epigenetic factors
other than Aph-1b will likely contribute to the suscepti-
bility for apomorphine. We now indeed found a correlation
between the newly identiﬁed genetic variations and the
apomorphine susceptibility in the Wistar population, con-
ﬁrming our hypothesis that apomorphine susceptibility is
caused by a number of genetic and epigenetic factors. A
combination of the newly identiﬁed variations may have
thus initially contributed to the degree of apomorphine
susceptibility in the original Wistar rat population.
Subsequent apomorphine injections to determine the
susceptibility for the drug during the breeding of the APO-
SUS and -UNSUS lines may have acted as an environ-
mental stressor, triggering the Aph-1b recombination event
at the topoisomerase II binding site only in rats with a high
susceptibility for apomorphine. The induced gene-dosage
imbalance of the Aph-1b gene, probably in combination
with other genetic or epigenetic factors, could then have
led to the complex phenotype observed in the APO-SUS
rats.
In conclusion, the present ﬁndings suggest that psy-
chopathological disturbances may be the result of multiple
genetic as well as epigenetic factors. We infer that our
newly identiﬁed variations are susceptibility loci for
schizophrenia-like features in the rat and may give new
insights into the genetic and epigenetic background of
complex neurodevelopmental disorders.
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